DOP2010000053A - Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno - Google Patents

Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno

Info

Publication number
DOP2010000053A
DOP2010000053A DO2010000053A DO2010000053A DOP2010000053A DO P2010000053 A DOP2010000053 A DO P2010000053A DO 2010000053 A DO2010000053 A DO 2010000053A DO 2010000053 A DO2010000053 A DO 2010000053A DO P2010000053 A DOP2010000053 A DO P2010000053A
Authority
DO
Dominican Republic
Prior art keywords
pirrolidin
ona
derivatives
receiver modulators
androgen
Prior art date
Application number
DO2010000053A
Other languages
English (en)
Inventor
Atsushi Hasuoka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2010000053A publication Critical patent/DOP2010000053A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto representado por la formula (I) de acuerdo con la reivindicación I o una sal de él, que tiene una acción moduladora superior del receptor de andrógeno.
DO2010000053A 2007-08-07 2010-02-05 Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno DOP2010000053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007205966 2007-08-07
JP2007299658 2007-11-19

Publications (1)

Publication Number Publication Date
DOP2010000053A true DOP2010000053A (es) 2010-07-15

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000053A DOP2010000053A (es) 2007-08-07 2010-02-05 Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno

Country Status (35)

Country Link
US (2) US8420694B2 (es)
EP (1) EP2176220B1 (es)
JP (1) JP5292390B2 (es)
KR (1) KR20100049644A (es)
CN (1) CN101821235B (es)
AR (1) AR067823A1 (es)
AU (1) AU2008284662B2 (es)
BR (1) BRPI0814957B8 (es)
CA (1) CA2695852C (es)
CL (1) CL2008002313A1 (es)
CO (1) CO6160326A2 (es)
CR (1) CR11266A (es)
CY (1) CY1114067T1 (es)
DK (1) DK2176220T3 (es)
DO (1) DOP2010000053A (es)
EA (1) EA017429B1 (es)
ES (1) ES2406685T3 (es)
GE (1) GEP20125571B (es)
HK (1) HK1143972A1 (es)
HR (1) HRP20130374T1 (es)
JO (1) JO2864B1 (es)
MA (1) MA31639B1 (es)
ME (1) ME01579B (es)
MX (1) MX2010001484A (es)
MY (1) MY159910A (es)
NZ (1) NZ583624A (es)
PE (1) PE20090899A1 (es)
PL (1) PL2176220T3 (es)
PT (1) PT2176220E (es)
RS (1) RS52812B (es)
SI (1) SI2176220T1 (es)
TN (1) TN2010000062A1 (es)
TW (1) TWI418543B (es)
WO (1) WO2009020234A2 (es)
ZA (1) ZA201001289B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2406685T3 (es) * 2007-08-07 2013-06-07 Takeda Pharmaceutical Company Limited Derivados de pirrolidin-2-ona como moduladores de los receptores de andrógenos
US8268872B2 (en) * 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
UY31736A (es) * 2008-03-26 2009-11-10 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
WO2011143469A1 (en) 2010-05-12 2011-11-17 Radius Health,Inc Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) * 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
WO2013152170A1 (en) * 2012-04-04 2013-10-10 Catylix, Inc. Selective androgen receptor modulators
CN107184569A (zh) * 2012-08-09 2017-09-22 迪纳米斯治疗公司 保持或改善对象健康、幸福和/或生理功能的方法
CN104662124B (zh) * 2012-09-21 2017-06-16 默克专利股份有限公司 具有c‑c三键的化合物及其在液晶混合物中的用途
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
DK3122426T3 (da) 2014-03-28 2023-04-03 Univ Duke Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
KR101597327B1 (ko) 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
EP4066827A1 (en) 2016-06-22 2022-10-05 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
MX2019007748A (es) 2017-01-05 2019-09-09 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
EP1122242B1 (en) * 1998-09-22 2008-01-16 Astellas Pharma Inc. Cyanophenyl derivatives
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
JP4605557B2 (ja) 2001-12-06 2011-01-05 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲンレセプタ修飾因子を用いた筋萎縮治療
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
EP1466902A4 (en) 2001-12-28 2005-11-09 Takeda Pharmaceutical ANTAGONISTS OF THE ANDROGEN RECEPTOR
GEP20074191B (en) 2002-06-17 2007-09-10 Univ Tennessee Res Foundation N-bridged selective androgen receptor modulators and methods of use thereof
CA2495383A1 (en) * 2002-08-12 2004-02-26 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
WO2005090282A1 (en) * 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US20080045504A1 (en) * 2004-05-11 2008-02-21 Pfizer Products Inc. Benzonitrile Derivatives to Treat Musculoskeletal Frailty
ZA200610270B (en) 2004-05-17 2008-06-25 Acadia Pharm Inc Androgen receptor modulators and method of treating disease using the same
DK2289872T3 (en) 2004-06-07 2017-10-09 Univ Tennessee Res Found Medical use of a selective androgen receptor modulator
CA2594340C (en) 2005-01-10 2015-11-10 Acadia Pharmaceuticals Inc. Aminophenyl derivatives as selective androgen receptor modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
PT1891038E (pt) 2005-05-13 2008-12-02 Lilly Co Eli N-arilpirrolidinas substituídas como moduladores selectivos do receptor de androgénio
US8592452B2 (en) 2005-08-01 2013-11-26 Takeda Pharmaceutical Company Limited Cyclic amine compound
US20090042857A1 (en) 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
JP2009543871A (ja) * 2006-07-19 2009-12-10 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 選択的アンドロゲン受容体調節薬、その類似体及び誘導体とそれらの使用
CN101516365A (zh) 2006-07-26 2009-08-26 诺瓦提斯公司 十一异戊二烯基焦磷酸酯合酶的抑制剂
CA2670976C (en) 2006-11-30 2015-01-27 Atsushi Hasuoka Cyclic amine compound
ES2406685T3 (es) 2007-08-07 2013-06-07 Takeda Pharmaceutical Company Limited Derivados de pirrolidin-2-ona como moduladores de los receptores de andrógenos

Also Published As

Publication number Publication date
US7834051B2 (en) 2010-11-16
PT2176220E (pt) 2013-04-09
HK1143972A1 (en) 2011-01-21
JO2864B1 (en) 2015-03-15
CO6160326A2 (es) 2010-05-20
TW200916439A (en) 2009-04-16
US20090042967A1 (en) 2009-02-12
MA31639B1 (fr) 2010-08-02
EA201070246A1 (ru) 2010-08-30
CR11266A (es) 2010-03-22
CN101821235B (zh) 2012-11-14
TWI418543B (zh) 2013-12-11
CN101821235A (zh) 2010-09-01
RS52812B (en) 2013-10-31
EA017429B1 (ru) 2012-12-28
MX2010001484A (es) 2010-03-04
ME01579B (me) 2014-09-20
US20110098336A1 (en) 2011-04-28
ZA201001289B (en) 2011-04-28
CL2008002313A1 (es) 2009-05-15
SI2176220T1 (sl) 2013-05-31
ES2406685T3 (es) 2013-06-07
CY1114067T1 (el) 2016-07-27
PL2176220T3 (pl) 2013-08-30
KR20100049644A (ko) 2010-05-12
CA2695852C (en) 2017-01-03
HRP20130374T1 (en) 2013-05-31
NZ583624A (en) 2012-06-29
AU2008284662B2 (en) 2013-07-25
GEP20125571B (en) 2012-07-10
BRPI0814957B8 (pt) 2021-05-25
BRPI0814957B1 (pt) 2019-12-03
MY159910A (en) 2017-02-15
EP2176220B1 (en) 2013-03-27
PE20090899A1 (es) 2009-08-06
WO2009020234A2 (en) 2009-02-12
CA2695852A1 (en) 2009-02-12
AU2008284662A1 (en) 2009-02-12
TN2010000062A1 (en) 2011-09-26
JP5292390B2 (ja) 2013-09-18
WO2009020234A3 (en) 2009-04-16
AR067823A1 (es) 2009-10-21
DK2176220T3 (da) 2013-06-10
EP2176220A2 (en) 2010-04-21
JP2010535704A (ja) 2010-11-25
US8420694B2 (en) 2013-04-16
BRPI0814957A2 (pt) 2015-02-03

Similar Documents

Publication Publication Date Title
DOP2010000053A (es) Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno
BR112018010118A2 (pt) inibidores de cxcr2
CR20110432A (es) Pirimidinas fusionadas
UY32469A (es) Composiciones y metodos para modular la senda de señalizacion de wnt
EA201791359A1 (ru) Конъюгаты, связывающие белок-лекарственное средство, содержащие производные антрациклина
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
EA201071201A1 (ru) ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71
AU2011232516A8 (en) Chemical compounds
EA201300887A1 (ru) Модуляторы s1p
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
UY31688A1 (es) Plaguicidas
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
CR20120204A (es) Nuevo uso antitumoral de cabazitaxel
CO6491037A2 (es) Derivados de pirazinooxazepina
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
CR20110581A (es) Preparación de solido
AR103355A1 (es) Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística
AR103317A1 (es) Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina
EA201300513A1 (ru) Волокна для контролируемого разложения
ECSP13012535A (es) Compuesto heterocíclico y sus usos
CR20110275A (es) 3-aminociclopentancarboxamidas como moduladores del receptor quimiocina
UY34072A (es) Derivados sustituidos de indol
UY32711A (es) Nueva forma cristalina de pemirolast
TR201009168A2 (tr) Suda dağılan sefpodoksim proksetil formülasyonları.